Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.42 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12819717 | 0.95 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820137 | 0.94 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12819780 | 0.92 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12850188 | 0.92 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820144 | 0.92 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12819970 | 0.91 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820122 | 0.91 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820411 | 0.91 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12819618 | 0.90 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL12820412 | 0.89 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011035417-A1 | HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | AEGERA THERAPEUTICS INC. (CA) | 2011-03-31 | — | — | WO | disclosed |